Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 bill
Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range o
A healthy run of nine-figure private rounds for biotechs in the US has continued with an impressive $225 million Series B for immunotherapy specialist AltruBio.
Contineum Therapeutics has become the latest biotech to file for an initial public offering (IPO) in the US, hoping to raise $150 million for its early clinical-stage cand
Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2
AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im